Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
02 oct. 2024 16h05 HE
|
Codexis, Inc.
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of...
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
01 oct. 2024 07h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and...
Codexis Announces New Employment Inducement Grants
06 sept. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as...
Codexis to Participate in Upcoming Healthcare Conferences
03 sept. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor...
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
20 août 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel...
Codexis Announces New Employment Inducement Grants
16 août 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as...
Codexis Publishes FY2023 Sustainability Disclosures
15 août 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the publication of its inaugural sustainability...
Codexis Reports Second Quarter 2024 Financial Results
08 août 2024 16h05 HE
|
Codexis, Inc.
Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical...
Codexis to Report Second Quarter 2024 Financial Results on August 8
18 juil. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second...
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
01 juil. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with...